[
  {
    "ts": null,
    "headline": "Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News",
    "summary": "Shares of Avidity Biosciences surged to a record high Wednesday after the company showed its hand in the cardiovascular space.",
    "url": "https://finnhub.io/api/news?id=647cca4064a59435aef0a0f88173c8b52ecb61117e67892a96f6b44c2648d644",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731515081,
      "headline": "Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News",
      "id": 131329700,
      "image": "",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Shares of Avidity Biosciences surged to a record high Wednesday after the company showed its hand in the cardiovascular space.",
      "url": "https://finnhub.io/api/news?id=647cca4064a59435aef0a0f88173c8b52ecb61117e67892a96f6b44c2648d644"
    }
  },
  {
    "ts": null,
    "headline": "Is Bristol-Myers Squibb Company (BMY) Among The Top Dividend Contenders Right Now?",
    "summary": "We recently compiled a list of the Dividend Contenders List: Top 15. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other dividend contenders. Dividend stocks have long been favored by investors for the income they generate, and they become even more appealing when dividends increase […]",
    "url": "https://finnhub.io/api/news?id=384ea2e3683efaf40eeaf489f1d91c1e9d958a476bf043e5a8a549165e096be5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731517875,
      "headline": "Is Bristol-Myers Squibb Company (BMY) Among The Top Dividend Contenders Right Now?",
      "id": 131336086,
      "image": "https://s.yimg.com/ny/api/res/1.2/ZsrqNB_sdV78LPtS9DZ12A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the Dividend Contenders List: Top 15. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other dividend contenders. Dividend stocks have long been favored by investors for the income they generate, and they become even more appealing when dividends increase […]",
      "url": "https://finnhub.io/api/news?id=384ea2e3683efaf40eeaf489f1d91c1e9d958a476bf043e5a8a549165e096be5"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors",
    "summary": "Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=7840264d7e2c781b90c05e877465218f6aca7e2428c6141e4a746cbf3303960a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731516060,
      "headline": "Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors",
      "id": 131417101,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=7840264d7e2c781b90c05e877465218f6aca7e2428c6141e4a746cbf3303960a"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson: Tracking Well Above The Industry",
    "summary": "Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating from financial writer. Read more here.",
    "url": "https://finnhub.io/api/news?id=b93cf744417e6816b73bb9510095e2913406cda0e8427554ff425e4123bc4232",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731489024,
      "headline": "Johnson & Johnson: Tracking Well Above The Industry",
      "id": 131324406,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413108793/image_1413108793.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating from financial writer. Read more here.",
      "url": "https://finnhub.io/api/news?id=b93cf744417e6816b73bb9510095e2913406cda0e8427554ff425e4123bc4232"
    }
  },
  {
    "ts": null,
    "headline": "Moat Stocks Review: Navigating Bonds, Beauty And Battleships",
    "summary": "Despite some volatility towards the month's end, investor sentiment remained cautiously optimistic. Click here to read more.",
    "url": "https://finnhub.io/api/news?id=1779925d7c9fad2e11bd404966950d0471e465da2090e1300ee54986691a5f7b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731470400,
      "headline": "Moat Stocks Review: Navigating Bonds, Beauty And Battleships",
      "id": 131319934,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1164810926/image_1164810926.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Despite some volatility towards the month's end, investor sentiment remained cautiously optimistic. Click here to read more.",
      "url": "https://finnhub.io/api/news?id=1779925d7c9fad2e11bd404966950d0471e465da2090e1300ee54986691a5f7b"
    }
  }
]